Pairing QuantiFERON gold in-tube with opt-out HIV testing in a tuberculosis contact investigation in the southeastern United States

AIDS Patient Care and STDs

Volumn 24, Issue 9, 2010, Pages 539-543

  Person, Anna K ^a   Goswami, Neela D ^a   Bissette, Deborah J ^b   Turner, Debra S ^b   Baker, Ann V ^b   Gadkowski, L Beth ^a   Naggie, Susanna ^a   Erlandson, Kirby ^c   Chen, Luke ^a   Lalani, Tahaniyat ^a   Cox, Gary M ^a   Stout, Jason E ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Wake County Human Services   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEAT INDUSTRY; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES; VIRUS DIAGNOSIS;

ADULT; AGED; CONTACT TRACING; CROSS-SECTIONAL STUDIES; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; SOUTHEASTERN UNITED STATES; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY; VIRAL LOAD; YOUNG ADULT;

EID: 77956308063     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2010.0102     Document Type: Article

References (26)

1. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-550.
2. Pape JW, Jean SS, Ho JL, et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-272.
3. Jensen PA, Lambert LA, Iademarco MF, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005;54: 1-141.
4. Lee SS, Liu YC, Huang TS, et al. Comparison of the interferon-gamma release assay and the tuberculin skin test for contact investigation of tuberculosis in BCG-vaccinated health care workers. Scand J Infect Dis 2008; 40:373-380.
5. Diel R, Loddenkemper R, Meywald-Walter K, et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008;177:1164-1170.
6. Harada N, Nakajima Y, Higuchi K, et al. Screening for tuberculosis infection using whole-blood interferon-gamma and Mantoux testing among Japanese healthcare workers. Infect Control Hosp Epidemiol 2006;27:442-448.
7. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: A randomized trial. Ann Intern Med 2008;149:689-697.
8. Horsburgh CR, Jr., Goldberg S, Bethel J, et al. Latent tuberculosis infection treatment acceptance and completion in the United States and Canada. Chest 2010;137:401-409.
9. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: An update. Ann Intern Med 2008;149:177-184.
10. de Perio MA, Tsevat J, Roselle GA, et al. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med 2009;169:179-187.
11. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: A cost-effectiveness analysis. Int J Tuberc Lung Dis 2007;11: 16-26.
12. Marra F, Marra CA, Sadatsafavi M, et al. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis 2008;12:1414-1424.
13. Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest 2007;131: 1424-1434.
14. Diel R, Wrighton-Smith P, Zellweger JP. Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis. Eur Respir J 2007;30:321-332.
15. Pathan AA, Wilkinson KA, Klenerman P, et al. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: Associations with clinical disease state and effect of treatment. J Immunol 2001;167:5217-5225.
16. Aiken AM, Hill PC, Fox A, et al. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis 2006;6:66.
17. Carrara S, Vincenti D, Petrosillo N, et al. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 2004;38:754-756.
18. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55:1-17; quiz CE11-14.
19. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005;352: 570-585.
20. Reichler MR, Bur S, Reves R, et al. Results of testing for human immunodeficiency virus infection among recent contacts of infectious tuberculosis cases in the United States. Int J Tuberc Lung Dis 2003;7:S471-478.
21. Bowen EF, Rice PS, Cooke NT, et al. HIV seroprevalence by anonymous testing in patients with Mycobacterium tuberculosis and in tuberculosis contacts. Lancet 2000;356:1488-1489.
22. Suggaravetsiri P, Yanai H, Chongsuvivatwong V, et al. Integrated counseling and screening for tuberculosis and HIV among household contacts of tuberculosis patients in an endemic area of HIV infection: Chiang Rai, Thailand. Int J Tuberc Lung Dis 2003;7:S424-431.
23. White DA, Scribner AN, Huang JV. A comparison of patient acceptance of fingerstick whole blood and oral fluid rapid HIV screening in an emergency department. J Acquir Immune Defic Syndr 2009;52:75-78.
24. Weis KE, Liese AD, Hussey J, et al. A routine HIV screening program in a South Carolina community health center in an area of low HIV prevalence. AIDS Patient Care STDs 2009;23:251-258.
25. Cunningham CO, Doran B, DeLuca J, et al. Routine opt-out HIV testing in an urban community health center. AIDS Patient Care STDs 2009;23:619-623.
26. Sena AC, Hammer JP, Wilson K, et al. Feasibility and acceptability of door-to-door rapid HIV testing among latino immigrants and their HIV risk factors in North Carolina. AIDS Patient Care STDs 2010;24:165-173.